Clinical trials: Disorder of Upper Respiratory System
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above
This is a non-randomized, open-label, externally controlled study to evaluate the safety and immnunogenicity of the Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above with no vaccination…
- Trial name
- COVID-19 (NCT05365724)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COPD, Upper Extremity
Cognitive Impairment and Upper Extremity Performance in COPD
Within the scope of this study, COPD patients will be divided into two groups according to cognitive dysfunction. Pulmonary function test, COPD assessment scale, Mini-Mental State Examination and Montreal Cognitive Assessment…
- Conditions
- COPD, Upper Extremity, Upper Limb Function, Cognitive Impairment
- Trial name
- COPD (NCT05137483)
- Testing
- Functional tests
- Volunteers
- 80 people
- Sponsor
- Izmir Katip Celebi University
Healthy
Head Position Angles in Children
Inexperienced rescuers may encounter severe problems in an unconscious patient in opening and maintaining an upper airway patent.
- Trial name
- NCT00532636
- Testing
- Ventilation
- Where
- Austria
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
COVID-19
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1…
- Trial name
- NCT05293548
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09), Inactivated COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19
Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above
This is a multi-center, case-driven, randomized, double-blinded, and placebo-controlled Phase Ⅲb clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate…
- Trial name
- NCT05156632
- Testing
- Medium-dosage COVID-19 Vaccine,Inactivated, High-dosage COVID-19 Vaccine,Inactivated
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study.
- Trial name
- NCT05664932
- Testing
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Influenza, Human, Infections
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine.
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05875961
- Testing
- Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59
- Where
- 7 sites in United States, Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seqirus
Sleep Apnea, Obstructive
BAY2586116 Nasal Spray and OSA Severity
This investigator-initiated study aims to determine the effects of BAY2586116 (a novel TASK channel blocker nasal spray) on sleep apnoea severity and the potential influence of route of breathing.
- Trial name
- NCT05527457
- Testing
- BAY2586116
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Flinders University
Respiratory Tract Diseases
Impact of C-reactive Protein Micromethod Testing in Primary Care on Antibiotics Delivery in Patients With Upper or Lower Respiratory Tract Infections
The project is a pragmatic approach to primary care. The main objective is to evaluate the impact of making a CRP measurement device available in primary care general practices on antibiotic prescribing for upper respiratory…
- Trial name
- ICARE (NCT07632651)
- Testing
- Quick test
- Where
- France
- Volunteers
- 140 people
- Sponsor
- MSPU des 3 Provinces
Obstructive Sleep Apnea Syndrome
Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients
In this open prospective study 40 patients who received Mandibular Replacement Appliance (MRA) Therapy as treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) will be included.
- Trial name
- NCT01524510
- Testing
- CT scan, Alice PDx polygraphy
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Antwerp
COVID-19
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
- Trial name
- NCT05313022
- Testing
- ZR-202-CoV
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Healthy Volunteers, Influenza
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness.
- Trial name
- NCT07779408
- Testing
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Where
- 16 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19 Pneumonia
Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
phase I study will evaluate the safety and tolerability of GEN2-Recombinant COVID-19 Vaccine (CHO cells) in healthy people aged 18 years and older.
- Trial name
- NCT05408312
- Testing
- Experimental Vaccine 1, Experimental Vaccine 2, Experimental Vaccine 3
- Where
- China
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Upper Respiratory Tract Infection, Prevention
Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children
Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper…
- Trial name
- NCT07154992
- Testing
- Probiotic - Lacticaseibacillus rhamnosus CRL1505
- Where
- Spain
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Bioithas SL
Inflammation, Cough
Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime…
- Conditions
- Inflammation, Cough, Rhinitis
- Trial name
- NCT01177852
- Testing
- diphenhydramine + dropropizine + pseudoephedrine, Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
COVID-19
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
This trial adopts a randomized, double-blind and positive control design, it is planned to recruit 1800 healthy participants who have been vaccinated with 2/3 doses of COVID-19 inactivated vaccine or mRNA vaccine for 3 months.
- Trial name
- COVID-19 (NCT05382871)
- Testing
- BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Hong Kong
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Hypertension, Pulmonary, Diseases of Mitral Valve
Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)
The purpose of this study is to determine whether Sildenafil is effective in the treatment of sustained pulmonary artery hypertension after corrected mitral valve disease.
- Trial name
- SUPERIOR (NCT02435303)
- Testing
- Sildenafil
- Volunteers
- 2 people
- Sponsor
- Asan Medical Center
Influenza, Viral Respiratory Infection
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
A multicenter, randomized, double-blind, placebo controlled comparative study to evaluate the safety, tolerability and efficacy of XC221 used at 100 mg daily and at 200 mg daily in patients with uncomplicated influenza or other…
- Conditions
- Influenza, Viral Respiratory Infection, Acute Viral Upper Respiratory Infections
- Trial name
- NCT05030324
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 9 sites in Russia
- Volunteers
- 255 people
- Sponsor
- Valenta Pharm JSC
COVID-19
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity
- Trial name
- NCT05911061
- Testing
- High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), control group
- Volunteers
- 4,950 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Acute Cough, Upper Respiratory Tract Infection
Observational Study of SIROPSEDAL in Acute Cough
This prospective, multicenter, observational post-market clinical follow-up study evaluates the performance and safety of SIROPSEDAL in children and adults with acute cough treated in routine clinical practice.
- Conditions
- Acute Cough, Upper Respiratory Tract Infection, Common Cold
- Trial name
- SIROPSEDAL (NCT07625683)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Laboratoires Elerte